Related Experiment Videos
The national cholesterol education program adult treatment panel ill guidelines
1Office of the Dean, Texas College of Osteopathic Medicine, University of North Texas Health Science Center at Fort Worth, 76107-2699, USA. mclearfi@hsc.unt.edu
Insights
Coronary heart disease (CHD) is a leading cause of death, with dyslipidemia as a primary risk factor. New National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines offer improved risk assessment and treatment strategies for lipid disorders.
Area of Science:
- Cardiology
- Public Health
Background:
- Coronary heart disease (CHD) is the leading cause of death in the U.S., with dyslipidemia as a primary modifiable risk factor.
- Over 65 million Americans require lipid-modification therapy, highlighting the need for effective management strategies.
Purpose of the Study:
- To review the new National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines released in 2001.
- To highlight the impact of these updated guidelines on osteopathic physicians and patient care.
Main Methods:
- The article reviews evidence-based recommendations from the NCEP ATP III guidelines.
- Key features of the guidelines, including CHD risk scoring and metabolic syndrome identification, are discussed.
Main Results:
- The NCEP ATP III guidelines introduce a CHD risk scoring system and identify CHD risk equivalents.
- Lower treatment target goals and an emphasis on conditions like metabolic syndrome are emphasized, increasing the number of patients eligible for intervention.
Conclusions:
- The NCEP ATP III guidelines enhance CHD risk assessment, leading to broader eligibility for lifestyle and drug interventions.
- These updated recommendations are crucial for physicians in managing lipid disorders and reducing CHD burden.
Abstract:
Coronary heart disease (CHD) remains the leading cause of death in the United States with more than 40% of all deaths each year directly attributed to the disease. Current evidence suggests that early identification and aggressive modification of risk factors offer the most promising approach to reducing the burden of CHD. Dyslipidemia has been identified as the primary risk factor leading to the development of CHD. It is estimated that nearly 65 million Americans require some form of lipid-modification therapy. The National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) set of guidelines released in May 2001 provides physicians with evidence-based recommendations on the classification, diagnosis, and treatment of lipid disorders. New features of the guidelines include a scoring system for calculating CHD risk, as well as the identification of CHD risk equivalents, lower treatment target goals, and an emphasis on conditions conferring a higher risk for CHD, such as the metabolic syndrome. The ATP III emphasis on risk assessment substantially increases the number of patients considered at risk for CHD and will expand the number eligible for lifestyle and drug interventions. This article highlights the new recommendations and reviews the impact of ATP III on osteopathic physicians.